Douay L, Giarratana M C, Drouet X, Bardinet D, Gorin N C
Formation associée Claude Bernard sur les Greffes de cellules souches hématopoiétiques, CHU Saint-Antoine, Paris, France.
Br J Haematol. 1991 Sep;79(1):27-32. doi: 10.1111/j.1365-2141.1991.tb08002.x.
We have previously reported prolonged in vitro maintenance of human bone marrow progenitor cells using a serum-free (SF) liquid culture system. The present study was undertaken to determine recombinant growth factor (rGF) requirement of long-term marrow culture (LTMC) in absence of exogenous serum, to avoid interference of any undefined components. Our data clearly show that the presence of serum is a major obstacle to the correct evaluation of rGF activity. However, in SF conditions the sequential analysis of these rGFs, alone or in combination, clearly showed a stimulating activity of interleukin 3 (IL3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) on granulopoiesis and erythropoiesis. Indeed, the cumulative number of progenitors recovered during an 8-week period exceeded the initial input by a factor of 1.7 for granulocyte-macrophage (CFU-GM), of 3 for erythroid blast-forming units (BFU-E) and of 5.45 for CFU-E when EPO, GM-CSF and IL3 were combined. This study has confirmed that the system is able to sustain haematopoiesis for 8 weeks in a way similar to that in serum-dependent LTMC, despite diminished stromal adherent layer development which never covered more than 50% of the flask surface. We conclude that this defined SF-LTMC system provides a reproducible technique for studying human haematopoiesis.
我们之前曾报道过使用无血清(SF)液体培养系统在体外长时间维持人骨髓祖细胞。本研究旨在确定在无外源性血清的情况下长期骨髓培养(LTMC)对重组生长因子(rGF)的需求,以避免任何不确定成分的干扰。我们的数据清楚地表明,血清的存在是正确评估rGF活性的主要障碍。然而,在无血清条件下,对这些rGF单独或联合进行的序贯分析清楚地显示,白细胞介素3(IL3)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和促红细胞生成素(EPO)对粒细胞生成和红细胞生成具有刺激活性。事实上,当EPO、GM-CSF和IL3联合使用时,在8周内回收的祖细胞累积数量,粒细胞-巨噬细胞(CFU-GM)超过初始接种量的1.7倍,红系爆式集落形成单位(BFU-E)超过3倍,红细胞集落形成单位(CFU-E)超过5.45倍。本研究证实,尽管基质贴壁层发育减少,从未覆盖超过培养瓶表面的50%,但该系统仍能够以类似于依赖血清的LTMC的方式维持造血8周。我们得出结论,这种明确的无血清LTMC系统为研究人类造血提供了一种可重复的技术。